References
- RehfeldJF, BardramL, BlankeS et al. Peptide hormone processing in tumours: biogenetic and diagnostic implications. Tumour Biol. 14, 174–183 (1993).
- RehfeldJF, GoetzeJP. The posttranslational phase of gene expression: new possibilities in molecular diagnosis. Curr. Mol. Med. 3, 25–38 (2003).
- WalshCT. Posttranslational Modifications of Proteins. Roberts and Company Publishers, CO, USA, 1–477 (2006).
- KastinAJ, MinaminoN ( Eds). Handbook of Biologically Active Peptides: Peptide Biosynthesis/Processing, Academic Press/Elsevier, CA, USA, 1711–1835 (2013).
- HansenLH, MadsenTD, GothCK et al. Discovery of O-glycans on atrial natriuretic peptide (ANP) that affects both its proteolytic degradation and potency at its cognate receptor. J. Biol. Chem. 294, 12567–12578 (2019).
- RehfeldJF. The art of measuring gastrin in plasma: a dwindling diagnostic discipline?Scand. J. Clin. Lab. Invest. 68, 353–361 (2008).
- RehfeldJF, GingrasMH, BardramL, HilstedL, GoetzeJP, PoitrasP. The Zollinger–Ellison syndrome and mismeasurement of gastrin. Gastroenterology 40, 1444–1453 (2011).
- SchechterI. Mapping of the combining sites of antibodies specific for poly-L-alanine determinants. Nature 228, 639–641 (1970).
- BardramL, RehfeldJF. Processing-independent radioimmunoanalysis: a general analytical principle applied to progastrin and its products. Anal. Biochem. 175, 537–543 (1988).
- PaloheimoLI, RehfeldJF. A processing-independent assay for human procholecystokinin and its products. Clin. Chim. Acta 229, 49–65 (1994).
- GoetzeJP, KastrupJ, PedersenF, RehfeldJF. Quantification of pro-B-type natriuretic peptide and its products in human plasma by use of an analysis independent of precursor processing. Clin. Chem. 48, 1035–1042 (2002).
- BørglumT, RehfeldJF, DrivsholmLB, HilstedL. Processing-independent quantitation of chromogranin A in plasma from patients with neuroendocrine tumors and small-cell lung carcinomas. Clin. Chem. 53, 438–446 (2007).
- HelleKB. Chromogranins A and B and secretogranin II as prohormones for regulatory peptides from the diffuse neuroendocrine system. Results Probl. Cell Differ. 50, 21–44 (2010).
- HoejLB, ParknerT, KnudsenCS, GrønbaekH. A comparison of three chromogranin A assays in patients with neuroendocrine tumours. J. Gastrointestin. Liver Dis. 23, 419–424 (2014).
- McGavranMH, UngerRH, RecantL, PolkHC, KiloC, LevinME. A glucagon-secreting alpha-cell carcinoma of the pancreas. N. Engl. J. Med. 274, 1408–1413 (1966).
- RehfeldJF, FederspielB, BardramL. A neuroendocrine tumor syndrome from cholecystokinin secretion. N. Engl. J. Med. 368, 1165–1166 (2013).
- AlbrechtsenNJ, VeedfaldS, PlamboeckA et al. Inability of some commercial assays to measure suppression of glucagon secretion. J. Diabetes Res. doi: 10.1155/2016/8352957 (2016).
- BakMJ, AlbrechtsenNJ, PedersenJ et al. Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies. Diabetes Obes. Metab. 16, 1155–1164 (2014).
- RehfeldJF. Measurement of cholecystokinin in plasma with reference to obesity studies. Nutr. Res. doi.org 10.1016/j.nutres.2020.01.003 (2020).